Rhizen enters into licensing agreement with Chinese biopharmaceutical company

Please login or
register
14.10.2020
symbolic picture china

Rhizen Pharmaceuticals, based in La-Chaux-de-Fonds, and Curon Biopharmaceutical Limited, a clinical-stage innovative biopharmaceutical company with facility in Shanghai have entered into an exclusive licensing agreement for the development and commercialization of Tenalisib in the Greater China region. Rhizen will will receive up to CHF150 million plus royalities.

Curon obtains the exclusive development and commercialization rights of Tenalisib for Greater China across all oncology indications, and will lead the clinical development in that territory by leveraging its unique expertise in translational research, clinical development and regulatory registration and its extensive research collaboration experience, to accelerate the development of and regulatory approval of this product in Greater China.

Under the terms of the agreement, Rhizen will receive an undisclosed upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of USD 149.5 million plus double-digit royalties on annual net sales of Tenalisib.   

Tenalisib (RP6530) is currently in Phase 2 clinical development for hematological malignancies. Tenalisib has been granted US FDA Fast Track & Orphan-Drug Designations for treatment of relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.

“Tenalisib has demonstrated great efficacy in lymphoma patients with outstanding safety profile, in-licensing this product to China would bring more effective and additional treatment options to Chinese cancer patients and greatly benefit these patients. Meanwhile, this will further enrich our diversified pipeline. We are very happy and look forward to closely collaborating with Rhizen to efficiently develop this molecule into an effective medicine to benefit patients not only in China but also around the world as soon as possible.” said Zhihong Chen, Ph.D., President of Curon.

0Comments

More news about

Rhizen Pharmaceuticals

rss